middle.news
Mayne Pharma’s NEXTSTELLIS® Gains PBS Listing, Slashing Costs for Australian Women
10:21am on Monday 29th of September, 2025 AEST
•
Pharmaceuticals
Read Story
Mayne Pharma’s NEXTSTELLIS® Gains PBS Listing, Slashing Costs for Australian Women
10:21am on Monday 29th of September, 2025 AEST
Key Points
PBS approval for NEXTSTELLIS® effective 1 October 2025
First contraceptive pill with natural estrogen estetrol (E4) reimbursed
Substantial patient cost reduction from over $328 to $31.60 per quarter
Supports Senate recommendation for broader contraceptive access
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE